Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 24, 2018

A Randomized, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Solriamfetol (JZP-110) for the Treatment of Excessive Sleepiness (ES) in Participants with Narcolepsy Types 1 and 2 (NT1/2) (CT.003)

MJ Thorpy, C Shapiro, G Mayer, BC Corser, H Emsellem, G Plazzi, D Chen, J Li, LP Carter, H Wang, J Black, Y Dauvilliers
First published April 9, 2018,
MJ Thorpy
1Montefiore Medical Center Bronx NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C Shapiro
2University of Toronto Toronto Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G Mayer
3Hephata Klinik Schwalmstadt Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BC Corser
4Sleep Management Institute Cincinnati OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H Emsellem
5Center for Sleep & Wake Disorders Chevy Chase MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G Plazzi
6University of Bologna Bologna Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D Chen
7Jazz Pharmaceuticals Palo Alto CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J Li
7Jazz Pharmaceuticals Palo Alto CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LP Carter
7Jazz Pharmaceuticals Palo Alto CA United States
8University of Arkansas for Medical Sciences Palo Alto CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H Wang
7Jazz Pharmaceuticals Palo Alto CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J Black
7Jazz Pharmaceuticals Palo Alto CA United States
9Stanford Center for Sleep Sciences and Medicine Palo Alto CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y Dauvilliers
10Gui-de-Chauliac Hospital CHU Montpellier France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
A Randomized, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Solriamfetol (JZP-110) for the Treatment of Excessive Sleepiness (ES) in Participants with Narcolepsy Types 1 and 2 (NT1/2) (CT.003)
MJ Thorpy, C Shapiro, G Mayer, BC Corser, H Emsellem, G Plazzi, D Chen, J Li, LP Carter, H Wang, J Black, Y Dauvilliers
Neurology Apr 2018, 90 (15 Supplement) CT.003;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: Phase 3 study to assess safety and efficacy of solriamfetol in participants with narcolepsy types 1 and 2 (NT1/2).

Background: Solriamfetol is a selective dopamine and norepinephrine reuptake inhibitor with wake-promoting effects. In 2 prior clinical studies, solriamfetol significantly improved wakefulness and reduced ES.

Design/Methods: A 12-week, double-blind, randomized, placebo-controlled, parallel-group study. Participants with or without cataplexy were randomized to receive solriamfetol 75 mg, 150 mg, 300 mg, or placebo for 12 weeks. Key eligibility criteria: NT1/2 diagnosis; mean sleep latency <25 minutes on the Maintenance of Wakefulness Test (MWT); Epworth Sleepiness Scale (ESS) score ≥10; nightly sleep time ≥6 hours. Key exclusion criteria: medications that could affect ES or cataplexy; nighttime or variable shift work; conditions besides NT1/2 that cause ES.

Results: Of 236 participants who received ≥1 dose of solriamfetol, 67.2% were female; 80.2% were white. Baseline ESS score was 17.2; baseline MWT mean sleep latency was 7.5 minutes. Solriamfetol significantly increased MWT sleep latency at week 12 (P<0.0001 for 300 mg and 150 mg). Least squares (LS) mean change from baseline to week 12 was 12.3 minutes for 300 mg, 9.8 for 150 mg, 4.7 for 75 mg, and 2.1 for placebo. Solriamfetol significantly decreased ESS scores at week 12 (P<0.0001 for 150 mg and 300 mg; P<0.05 for 75 mg). LS mean change from baseline in ESS was −6.4 for 300 mg, −5.4 for 150 mg, −3.8 for 75 mg, and −1.6 for placebo. Most common treatment-emergent adverse events (TEAEs; ≥5%) were headache, nausea, decreased appetite, nasopharyngitis, dry mouth, and anxiety. One participant in solriamfetol 150 mg group had 2 serious TEAEs considered unrelated to study drug (continued in study without dose modification). Discontinuations due to TEAEs were more frequent in solriamfetol 150 mg and 300 mg groups.

Conclusions: Solriamfetol improved wakefulness and reduced ES in participants with NT1/2. Safety and tolerability were consistent with previous studies of solriamfetol.

Study Supported by:

Jazz Pharmaceuticals.

Disclosure: Dr. Thorpy has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with has received consultancy fees from Jazz Pharmaceuticals, Merck & Co, Inc., and Teva Pharmaceutical Industries Ltd; and has been a member of the speakers’ bureau for Jazz Pharmaceuticals and Cephalon, Inc. (now Teva Pharmaceutical Industries, Ltd.). Dr. Thorpy has received research support from has received research/grant support and consultancy fees from Jazz Pharmaceuticals, Merck & Co, Inc., and Teva Pharmaceutical Industries Ltd. Dr. Shapiro has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with speakers’ bureau for Jazz Pharmaceuticals. Dr. Shapiro has received compensation for serving on the Board of Directors of board member, with stock/stock options, of Neurozone. Dr. Shapiro has received research support from received research funding from the National Institutes of Health and the Canadian Institutes of Health Research. Dr. Mayer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with speakers’ bureaus for UCB Pharma and Sanofi. Dr. Mayer has received compensation for serving on the Board of Directors of a board member of the European Narcolepsy Network. Dr. Mayer has received research support from honoraria from the Paul Ehrlich Institute, Germany. Dr. Corser has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with . BCC has received consultancy fees from and served on the speakers’ bureaus for Merck and Pernix. Dr. Emsellem has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with has received consultancy fees, honoraria, and/or has been a speakers’ bureau member for Jazz Pharmaceuticals, NightBalance, Philips North America, and Vanda Pharmaceuticals. Dr. Emsellem has received compensation for serving on the Board of Directors of is a board member of the National Sleep Foundation. Dr. Emsellem has received research support from has received research funding from Jazz Pharmaceuticals, Vanda Pharmaceuticals, Eisai, Flamel, and Merck & Co, Inc. Dr. Plazzi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Plazzi has participated in advisory boards for UCB and Jazz Pharmaceuticals. Dr. Chen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with DC is an employee of Jazz Pharmaceuticals who, in the course of this employment, has received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals plc. Dr. Li has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with JL is an employee of Jazz Pharmaceuticals who, in the course of this employment, has received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals plc. Dr. Carter has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with LPC is an employee of Jazz Pharmaceuticals who, in the course of this employment, has received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals plc. Dr. Wang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with HW was an employee of Jazz Pharmaceuticals who, in the course of this employment, had received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals plc. Dr. Black has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr Black is a part-time employee of Jazz Pharmaceuticals and shareholder of Jazz Pharmaceuticals plc. Dr. Dauvilliers has nothing to disclose.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Brain Metabolism Related to Mild Cognitive Impairment and Phenoconversion in Patients With Isolated REM Sleep Behavior Disorder

Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (22)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise